Bristol-Myers Squibb Co. (BMY) is set to face a pivotal FDA decision on March 6, 2026, regarding its supplemental New Drug Application for Sotyktu in the expanded indication of treating adults with active psoriatic arthritis.
Sotyktu (deucravacitinib), a first-in-class oral tyrosine kinase 2 (TYK2) inhibitor, was FDA-approved in September 2022 for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The drug works by selectively blocking TYK2, a key signaling enzyme mediating IL-23, IL-12, and Type I interferon pathways involved in immune and inflammatory responses.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.